plus-plus emphasis type-small-caps">l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study
详细信息 查看全文
- 作者：M. Florentin ; M. S. Elisaf ; C. V. Rizos ; V. Nikolaou ; E. Bilianou ; C. Pitsavos…
- 关键词：l ; Carnitine ; Lipoprotein (a) ; Simvastatin ; Triglycerides
- 刊名：Lipids
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：52
- 期：1
- 页码：1-9
- 全文大小：
- 刊物类别：Chemistry and Materials Science
- 刊物主题：Lipidology; Neurochemistry; Medical Biochemistry; Nutrition; Medicinal Chemistry; Microbial Genetics and Genomics;
- 出版者：Springer Berlin Heidelberg
- ISSN：1558-9307
- 卷排序：52
文摘
Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. There are currently limited therapeutic options to lower Lp(a) levels. l-Carnitine has been reported to reduce Lp(a) levels. The aim of this study was to compare the effect of l-carnitine/simvastatin co-administration with that of simvastatin monotherapy on Lp(a) levels in subjects with mixed hyperlipidemia and elevated Lp(a) concentration. Subjects with levels of low-density lipoprotein cholesterol (LDL-C) >160 mg/dL, triacylglycerol (TAG) >150 mg/dL and Lp(a) >20 mg/dL were included in this study. Subjects were randomly allocated to receive l-carnitine 2 g/day plus simvastatin 20 mg/day (N = 29) or placebo plus simvastatin 20 mg/day (N = 29) for a total of 12 weeks. Lp(a) was significantly reduced in the l-carnitine/simvastatin group [−19.4%, from 52 (20–171) to 42 (15–102) mg/dL; p = 0.01], but not in the placebo/simvastatin group [−6.7%, from 56 (26–108) to 52 (27–93) mg/dL, p = NS versus baseline and p = 0.016 for the comparison between groups]. Similar significant reductions in total cholesterol, LDL-C, apolipoprotein (apo) B and TAG were observed in both groups. Co-administration of l-carnitine with simvastatin was associated with a significant, albeit modest, reduction in Lp(a) compared with simvastatin monotherapy in subjects with mixed hyperlipidemia and elevated baseline Lp(a) levels.